



## **MEDIA ALERT**

### **Chronos CEO awarded 2016 Best European CEO in the Drug Discovery Industry**

**Oxford, UK, 02 February 2017:** Chronos Therapeutics Ltd (Chronos), the private biotech company focused on ageing diseases, brain and nervous system disorders, is honoured to announce that Dr Huw Jones, CEO of Chronos, has been awarded Best CEO in the European Drug Discovery Industry by online and print magazine European CEO.

Dr Jones was one of six finalists nominated anonymously for this prestigious award in 2016. The award follows a transformative year for Chronos with several key patents submitted, important pre-clinical data developing for the company's lead asset as well as the first acquisition which was concluded in July 2016. The innovative transaction saw Chronos acquiring global rights to three new chemical entity pre-clinical programmes targeting the Central Nervous System from a subsidiary of Shire PLC with the seller becoming a shareholder in the business in return.

**Dr Huw Jones, CEO of Chronos Therapeutics, commented:** *"This award recognises Chronos' team effort in developing and acquiring treatments for patients with degenerative and behavioural diseases. We are developing a re-purposed asset for the devastating disease ALS and actively searching for more discoveries in neurodegeneration. We recently concluded an innovative deal with Shire that adds value to Chronos and has the potential to alleviate significant suffering."*

Interview of the company is available at: <http://www.europeanceo.com/culture/chronos-therapeutics-acquisitions-bring-hope-for-diseases-of-ageing/>

### **Contacts**

#### **Chronos Therapeutics**

Dr Huw Jones, CEO  
Dr Helen Kuhlman, VP Corporate Development  
Tel: +44 (0) 1865-309-500

#### **Hume Brophy**

Conor Griffin, Alexia Faure, Alex Protsenko  
Tel: +44 (0) 20-7862-6381  
Email: [chronotherapeutics@humbrophy.com](mailto:chronotherapeutics@humbrophy.com)

### **Notes to Editors**

#### **About Chronos Therapeutics**

Chronos Therapeutics Ltd. is a privately held biotechnology company focused on diseases of ageing, brain and nervous system disorders. Chronos has a dedicated laboratory in



Oxford, which screens for activity of drugs in brain disease through its proprietary platform, Chronoscreen™.

It has an extensive library of re-purposed molecules showing promise for brain and neurological diseases. The lead compound, RDC5, is being developed for the fatal neurodegenerative disease, Amyotrophic Lateral Sclerosis (ALS).

Chronos recently acquired three new chemical entity (NCE) development programs for CNS diseases. The most advanced programme is initially targeting fatigue associated with multiple sclerosis with the others addressing behavioural and neurodegenerative conditions. Chronos' shareholders include the University of Oxford, Vulpes Testudo and Life Sciences funds, Odey European and Swan funds, a subsidiary of Shire PLC, the Board and Management.